Novavax vs Vir Biotechnology
NVAX and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVAX and VIR compare
Vir Biotechnology is the larger company, worth 1.2 times as much as Novavax ($1.7B against $1.4B).
Vir Biotechnology grew revenue faster over the last twelve months (1696% versus −61.3% for Novavax).
Novavax keeps more of each dollar of sales as profit, with a net margin of −18.6% compared with −61.0% at Vir Biotechnology.
Vir Biotechnology scores higher on the StockData Score (12 against 5 for Novavax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVAX | VIR |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $1.7B |
| Share price | $8.53 | $9.96 |
| Change, 1 year | 18.4% | 74.4% |
| Change, 5 years | −95.6% | −69.6% |
| Beta (5Y) | 1.92 | 0.72 |
| Employees | 749 | 367 |
| StockData Score | ||
| Total score | 5 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.4× (better) | 5.6× |
| P/B | – | 1.9× |
| FCF yield | – | −8.4% |
| Fair value | – | $12.60 |
| Margin of safety | – | 21.0% |
| Growth | ||
| Revenue growth (TTM) | −61.3% | 1696% (better) |
| Revenue growth, 5Y average | 18.8% (better) | −2.1% |
| Net income growth (TTM) | −122% | – |
| EPS growth (TTM) | −127% | – |
| Profitability | ||
| Gross margin | 78.0% | – |
| Operating margin | −21.2% (better) | −69.8% |
| Net margin | −18.6% (better) | −61.0% |
| FCF margin | – | −46.8% |
| Return on equity | – | −21.8% |
| Return on invested capital | – | −45.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.0× | – |
| Current ratio | 2.15 | 6.30 (better) |
| Altman Z-score | −5.94 | 3.11 (better) |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.2% | 86.6% |
| Held by insiders | 9.2% | 17.0% |
| Insider net buying, 12 months | – | −$4.0M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 30.9% | 12.0% |
Go deeper
- NVAX stock overview
- NVAX income statement
- NVAX valuation and score
- VIR stock overview
- VIR income statement
- VIR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.